Neurology
Found 17 results
Filters: Keyword is Multiple Sclerosis, Relapsing-Remitting  [Clear All Filters]
2023
Williams MJ, Okai AF, Cross AH, Monson NL, Vartanian T, Thrower BW, Reder AT, English JB, Wu GF, Bernitsas E et al..  2023.  Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial.. Mult Scler Relat Disord. 76:104794.
2022
Zinger N, Ponath G, Sweeney E, Nguyen TD, Lo CHung, Diaz I, Dimov A, Teng L, Zexter L, Comunale J et al..  2022.  Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions.. Neurol Neuroimmunol Neuroinflamm. 9(2)
Marcille M, Rúa SHurtado, Tyshkov C, Jaywant A, Comunale J, Kaunzner UW, Nealon N, Perumal JS, Zexter L, Zinger N et al..  2022.  Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis.. Sci Rep. 12(1):4411.
Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ.  2022.  Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.. CNS Drugs. 36(9):977-993.
Rúa SMHurtado, Kaunzner UW, Pandya S, Sweeney E, Tozlu C, Kuceyeski A, Nguyen TD, Gauthier SA.  2022.  Lesion features on magnetic resonance imaging discriminate multiple sclerosis patients.. Eur J Neurol. 29(1):237-246.
2021
Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D et al..  2021.  Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.. Adv Ther. 38(7):3724-3742.
2019
Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.  2019.  Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.. BMC Neurol. 19(1):116.
Zhang S, Nguyen TD, Rúa SMHurtado, Kaunzner UW, Pandya S, Kovanlikaya I, Spincemaille P, Wang Y, Gauthier SA.  2019.  Quantitative Susceptibility Mapping of Time-Dependent Susceptibility Changes in Multiple Sclerosis Lesions.. AJNR Am J Neuroradiol. 40(6):987-993.
2018
Azary S, Schreiner T, Graves J, Waldman A, Belman A, Guttman BWeinstock, Aaen G, Tillema J-M, Mar S, Hart J et al..  2018.  Contribution of dietary intake to relapse rate in early paediatric multiple sclerosis.. J Neurol Neurosurg Psychiatry. 89(1):28-33.
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
Chiang GC, Hu J, Morris E, Wang Y, Gauthier SA.  2018.  Quantitative Susceptibility Mapping of the Thalamus: Relationships with Thalamic Volume, Total Gray Matter Volume, and T2 Lesion Burden.. AJNR Am J Neuroradiol. 39(3):467-472.
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.. Mult Scler. 24(4):553-554.
2017
Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, You X, Wang P, Giannattasio G.  2017.  No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.. Mult Scler. 23(13):1736-1747.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K et al..  2017.  Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.. N Engl J Med. 376(3):221-234.
2016
Chiang GC, Pinto S, Comunale JP, Gauthier SA.  2016.  Gadolinium-Enhancing Lesions Lead to Decreases in White Matter Tract Fractional Anisotropy in Multiple Sclerosis.. J Neuroimaging. 26(3):289-95.
2013
Reardon J, Perumal JS.  2013.  Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.. Drug Des Devel Ther. 7:1187-93.
2012
Perumal JS, Foo F, Cook P, Khan O.  2012.  Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.. Mult Scler. 18(8):1197-9.